| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Zoetis Inc.$75.93
+1.23 (+1.65%)
0Pipeline Score NOT_PHARMA · Pre-Clinical
Market Cap
31.83 B
EPS
6.04
P/E Ratio
12.41 $
Value Trade
624.32 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.26 B
R&D Expenses
180.00 M
Operating CF
401.00 M
Total Assets
15.15 B
Total Liabilities
11.92 B
Equity
3.23 B
-1.37 %
Week
-1.71 %
1 Month
-14.12 %
3 Month
-40.83 %
6 Month
-53.94 %
5 Year
158.16 %
All Time
Cash Data
Cash Position
1.94 B
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
4.83 M
52 Week Range
71.47 - 160.48
% held by Insiders
0.56 %
% held by Institutions
98.91 %
Enterprise Value
38.48 B
Total Shares
419.00 M
Short %
4.91 %
Float Shares
382.55 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zoetis Inc.
235Total events
0Upcoming
133Tier-1 (high impact)
2019 – 2026Coverage
Event history 2
TBD
▲CHMP Positive OpinionPortelaApprovedEx-US Regulatory
Subscribe to view catalyst details
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
0
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 3%
Micro Cap (rank 896 of 923)
Percentile RankClinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZTS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ZTS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZTS▲ +1.7%today
Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer
Zoetis Inc. has appointed Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. This newly created role will see Saccaro leading the global finance function and overseeing Global Manufacturing and Supply. His responsibilities will include shaping financial strategy and enhancing operational performance.
Read more →ZTS▲ +1.7%today
Zoetis Announces Second Quarter 2026 Results
Zoetis Inc. has announced its financial results for the second quarter of 2026, reporting revenues of $2.5 billion, which is unchanged from the same period in 2025. The company's net income was reported at $691 million, reflecting a 5% decrease year-over-year. Despite these figures, there was a slight growth in earnings per share.
Read more →ZTSZoetis Launches Portela® (relfovetmab) in Canada and the European Union
Zoetis Inc. has launched Portela® (relfovetmab) in Canada and the EU, marking a significant advancement in veterinary medicine. This therapy is the first long-acting monoclonal antibody designed to relieve pain from osteoarthritis in cats, providing relief for up to three months with just one injection. The launch is supported by extensive research and development.
Read more →ZTSZoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
Zoetis Inc. has launched Lenivia® (izenivetmab injection) in Canada and the EU, a new long-acting monoclonal antibody therapy for osteoarthritis pain management. This innovative treatment can provide relief for up to three months with a single subcutaneous injection. The launch is supported by a decade of research and a successful nine-month European field study.
Read more →ZTSZoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities
Zoetis Inc. has announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. This acquisition builds on a previous partnership and will enhance Zoetis' Global Diagnostics portfolio. The integration will provide around-the-clock access to board-certified veterinary specialists, improving reference laboratory services.
Read more →ZTSZoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND
Zoetis has been granted marketing authorization by the European Commission for its Poulvac® Procerta® HVT-ND vaccine. This approval allows the company to market the vaccine in Europe, enhancing its portfolio in the poultry sector. The vaccine aims to provide protection against specific viral diseases in poultry.
Read more →ZTSZoetis to Host Webcast and Conference Call on Second Quarter 2026 Financial Results
Zoetis has announced a webcast and conference call to discuss its financial results for the second quarter of 2026. The event aims to provide insights into the company's performance and future outlook. Further details regarding the timing and access to the call will be provided by the company.
Read more →ZTSZoetis to Participate in Upcoming Investor Conferences
Zoetis is set to participate in several upcoming investor conferences. Details regarding the specific conferences and the content of their presentations have not been disclosed in the article. This participation indicates Zoetis's ongoing engagement with investors and stakeholders in the biopharma sector.
Read more →ZTSZoetis Declares Third Quarter 2026 Dividend
Zoetis has announced its third quarter dividend for 2026. The declaration is part of the company's ongoing commitment to return value to its shareholders. Further details about the dividend amount and payment date were not provided in the announcement.
Read more →ZTSInvestor Contacts Jennifer Albano Steve Frank 1-862-399-0810 (o) 1-973-822-7141 (o) jennifer.albano zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) la
Zoetis Inc. has declared a dividend of $0.53 per share for the third quarter of 2026, to be paid on September 1, 2026. Shareholders must be on record by July 20, 2026, to receive the dividend. The company, a leader in animal health, highlights its nearly 75-year legacy and commitment to innovative animal care. Forward-looking statements indicate that future results may vary due to potential risks and uncertainties.
Read more →ZTS▼ -21.5%on this news
Zoetis Announces First Quarter 2026 Results
Zoetis Inc. reported its Q1 2026 financial results, showing a 3% revenue increase to $2.3 billion, with net income at $601 million. The U.S. segment faced challenges, with an 8% revenue decline due to heightened competition and price sensitivity among pet owners. In contrast, the International segment saw a 17% revenue increase, driven by strong demand for companion animal products. The company remains optimistic about its pipeline of potential blockbusters and ongoing innovation efforts.
Read more →ZTS▼ -21.5%on this news
Zoetis Announces First Quarter 2026 Results Revenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis Adjusted Net Income o
Zoetis reported its financial results for Q1 2026, announcing revenue of $2.3 billion, representing a 3% growth from the previous year. Adjusted net income was $646 million, demonstrating an increase on a reported basis. However, the company's U.S. segment faced challenges, with an 8% decline in revenue attributed to heightened competition and price sensitivity among consumers. Conversely, the International segment saw strong growth of 17% in revenue. Zoetis revised its full-year revenue guidance, anticipating solid growth despite current challenges in the U.S. market.
Read more →ZTSZoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results
Zoetis has announced a webcast and conference call to discuss its financial results for the first quarter of 2026. The event aims to provide insights into the company's performance during this period. Further details regarding the timing and access to the call will likely be shared closer to the date.
Read more →ZTSZoetis to Participate in Upcoming March 2026 Investor Conferences
Zoetis Inc. has announced that Wetteny Joseph, the CFO, will participate in upcoming investor conferences in March 2026. Interested parties can access live audio webcasts of the presentations through the Zoetis investor website, with replays available afterward. This participation highlights Zoetis's commitment to engaging with investors and sharing insights about its operations.
Read more →ZTSZoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation
Zoetis Inc. has announced its agreement to acquire Neogen's animal genomics business for $160 million. This acquisition aims to enhance Zoetis' Precision Animal Health portfolio by integrating advanced genomic technologies. The deal is expected to close in the second half of 2026, pending regulatory approvals. The acquisition will bolster Zoetis' commitment to livestock innovation and customer value.
Read more →ZTSZoetis to Participate in the Bank of America Securities 2026 Animal Health Summit
Zoetis Inc. will participate in the Bank of America Securities 2026 Animal Health Summit on February 26, 2026. Wetteny Joseph, the Executive Vice President and CFO, will represent the company during the event. Interested parties can access a live audio webcast and a replay will be available afterward on Zoetis' website.
Read more →ZTSZoetis Reports Fourth Quarter and Full Year 2025 Results
Zoetis Inc. reported strong financial results for Q4 and full year 2025, with revenues of $2.4 billion and $9.5 billion, respectively. The company highlighted growth in adjusted net income and successful regulatory approvals for new osteoarthritis pain products. Looking ahead, Zoetis provided guidance for 2026 and emphasized its commitment to innovation and market expansion.
Read more →ZTSZoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results
Zoetis Inc. will host a webcast and conference call on February 12, 2026, to discuss its fourth quarter and full year 2025 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from analysts. The event will be accessible to the public via the company's investor website.
Read more →ZTSZoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast
Zoetis Inc. hosted an Innovation Webcast to discuss its R&D leadership and growth opportunities in animal health. CEO Kristin Peck emphasized the company's commitment to innovation and the importance of animals in society. The webcast featured key executives and showcased Zoetis's plans to advance therapies and solutions for animal care.
Read more →ZTS▼ -13.8%on this news
Zoetis Announces Third Quarter 2025 Results Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quart
Zoetis Inc. reported its financial results for the third quarter of 2025, showing a revenue of $2.4 billion, a 1% growth year-over-year. The company achieved an adjusted net income of $754 million, reflecting a 9% increase. Despite some declines in livestock product sales and certain products for osteoarthritis pain, Zoetis highlighted significant regulatory milestones including major product approvals and geographic expansions. The financial outlook for the year has been revised upward, projecting total revenue of $9.4 to $9.475 billion.
Read more →ZTSZoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook Reports Revenue of $2.5 Billion, Growing 4%, and Net Income of $718 Million, or $1.61 per Diluted Share, Increasing 15% and 18%, Respectively, o
Zoetis Inc. reported its financial results for the second quarter of 2025, showcasing a revenue of $2.5 billion and a net income of $718 million. The company also raised its full year revenue guidance to between $9.450 billion and $9.600 billion, driven by strong operational growth. Despite some challenges in livestock product sales and monoclonal antibody products, Zoetis highlighted significant increases in its adjusted net income and operational growth over the past year. Executives emphasized disciplined execution as key to future performance.
Read more →ZTS▼ -5.2%on this news
Zoetis Announces First Quarter 2025 Results Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quart
Zoetis Inc. reported its financial results for the first quarter of 2025, revealing a revenue of $2.2 billion, which represents a 1% increase year-over-year. Notably, the company achieved a 9% organic operational growth in revenue. Additionally, adjusted net income reached $662 million, highlighting a strong performance despite the challenges in the livestock product segment. The company also updated its revenue guidance for the full year to reflect various market conditions, including foreign exchange impacts and enacted tariffs.
Read more →ZTS▼ -5.1%on this news
Zoetis Reports Fourth Quarter and Full Year 2024 Results Reports Revenue of $2.3 Billion, Growing 5%, and Net Income of $581 Million, or $1.29 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis
Zoetis Inc. reported its financial results for the fourth quarter and full year 2024, showing a revenue increase of 5% in Q4 to $2.3 billion and an 8% rise for the full year to $9.3 billion. Net income rose by 11% to $581 million in Q4, with adjusted net income at $632 million. The company anticipates further growth in 2025, projecting revenues between $9.225 billion and $9.375 billion and encouraging operational growth. The results underscore the strength of Zoetis' product portfolio in both companion animals and livestock.
Read more →ZTSInvestor Contacts Jennifer Albano Steve Frank 1-973-945-4333 (o) 1-973-822-7141 (o) jennifer.albano zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) la
Zoetis Inc. has declared a dividend of $0.500 per share for Q2 2025, set to be paid on June 3, 2025, to stockholders on record by April 21, 2025. The company is recognized as a leader in animal health, with a commitment to advancing animal care for over 70 years. In 2023, Zoetis reported revenues of $8.5 billion, indicating significant financial performance. The announcement includes a note on forward-looking statements underscoring potential risks that might affect future performance.
Read more →ZTSZoetis Announces Third Quarter 2024 Results Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Qu
Zoetis Inc. reported its third quarter 2024 financial results, revealing a revenue of $2.4 billion, which is an 11% increase compared to the same period last year. The company's net income rose to $682 million or $1.50 per diluted share, marking a 14% growth on a reported basis. Zoetis also raised its full year guidance for revenue to between $9.200 billion and $9.300 billion. The results highlight strong operational growth in both the U.S. and international segments across its product portfolio.
Read more →ZTSInvestor Contacts Jennifer Albano Steve Frank 1- 862-399-0810 (o) 1-973-822-7141 (o) jennifer.albano zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) l
Zoetis Inc. has declared a dividend of $0.432 per share for the fourth quarter of 2024, with payment set for December 3, 2024. This decision reflects the company's strong financial performance, having generated $8.5 billion in revenue in 2023. As a leader in animal health for over 70 years, Zoetis is committed to advancing care for animals globally through its diverse portfolio of medicines and technologies. The company continues to support veterinarians and livestock farmers across more than 100 countries.
Read more →ZTS▲ +6%on this news
Zoetis Announces Second Quarter 2024 Results Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Qua
Zoetis Inc. reported its financial results for the second quarter of 2024, revealing a revenue of $2.4 billion, which is an 8% increase compared to the prior year. The company experienced operational growth of 11% in revenue and adjusted net income rose by 18% operationally. However, net income saw a decline of 7% on a reported basis. Zoetis also raised its full-year revenue guidance considerably due to strong performance, particularly in the companion animal segment.
Read more →ZTSInvestor Contacts Jenielle Alonso Steve Frank 1-973-945-4333 (o) 1-973-822-7141 (o) jenielle.alonso zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) la
Zoetis Inc. announced that its Board of Directors has declared a dividend of $0.432 per share for the third quarter of 2024, payable on September 4, 2024. This dividend will benefit all shareholders of record as of July 18, 2024. As a leading animal health company, Zoetis emphasizes its commitment to enhancing care for animals, supported by its significant revenue and extensive operating history. The announcement includes a reminder about potential forward-looking statements and associated risks.
Read more →ZTS▲ +5.5%on this news
Zoetis Announces First Quarter 2024 Results Reports Revenue of $2.2 Billion, Growing 10%, and Net Income of $599 Million, or $1.31 per Diluted Share, Increasing 9% and 10%, Respectively, on a Reported Basis for First Qua
Zoetis reported strong financial results for the first quarter of 2024, with revenues of $2.2 billion, up 10% year-over-year. The company also reported net income of $599 million, marking a 9% increase. Notably, operational growth was highlighted, with adjusted net income rising 15%. However, challenges were noted in the livestock segment as sales declined, prompting the company to reassess its strategic focus. Zoetis updated its full year guidance, aiming for operational growth of 8.5% to 10.5% and emphasizing investment in its companion animal portfolio.
Read more →ZTS▼ -6.7%on this news
Zoetis Reports Fourth Quarter and Full Year 2023 Results For Fourth Quarter 2023, Zoetis Reports Revenue of $2.2 Billion, Growing 8%, and Net Income of $525 Million, or $1.14 per Diluted Share, Increasing 14% and 15%, Re
Zoetis reported its financial results for the fourth quarter and full year of 2023, highlighting an 8% revenue increase to $2.2 billion for Q4. The company also achieved a net income of $525 million for Q4, marking a 14% rise year-over-year. Looking ahead, Zoetis provided guidance for 2024, anticipating revenue between $9.075 billion and $9.225 billion, with an operational growth forecast of 7% to 9%. The report also emphasized ongoing product innovations and approvals that are expected to drive further growth.
Read more →ZTSInvestor Contacts Jenielle Alonso Steve Frank 1-973-945-9333 (o) 1-973-822-7141 (o) jenielle.alonso zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) la
Zoetis Inc. has announced a dividend of $0.432 per share for the second quarter of 2024, payable to shareholders as of April 19, 2024. The company, a leader in animal health, continues to focus on innovative solutions for animal care, supported by a strong revenue stream of $8.1 billion in 2022. Additionally, Zoetis emphasizes its commitment to the well-being of animals globally through various products and technologies. The statement includes a cautionary note regarding forward-looking statements and associated risks.
Read more →ZTSInvestor Contacts Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (o) 1-973-443-2792 (o) laura.pan
Zoetis Inc. has declared a dividend of $0.432 per share for Q1 2024, representing a 15% increase from the previous year. This decision underscores the company's ongoing success driven by its robust product portfolio. The dividend will be paid to shareholders on March 1, 2024, for those on record by January 19, 2024. The move demonstrates Zoetis' commitment to providing returns to its investors. Additionally, forward-looking statements are made regarding potential risks and uncertainties in the future.
Read more →ZTS▲ +6.3%on this news
Zoetis Announces Third Quarter 2023 Results Reports Revenue of $2.2 Billion, Growing 7%, and Net Income of $596 Million, or $1.29 per Diluted Share, Increasing 13% and 14%, Respectively, on a Reported Basis for Third Qua
Zoetis Inc. reported robust financial results for the third quarter of 2023, with a revenue increase of 7% to $2.2 billion and a net income rise of 13% to $596 million. The company's operational metrics also showed strong growth, such as an 8% increase in revenue and a 13% increase in adjusted net income. However, the company has revised its full-year revenue guidance, citing foreign exchange impacts and reflected challenges in livestock sales. Overall, Zoetis expresses confidence in achieving its operational goals despite these external factors.
Read more →ZTSInvestor Contacts Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price zoetis.com steve.frank zoetis.com Laura Panza Nick Soonthornchai 1-973-975-5176 (c) 1-973-443-2792 (o) laura.pan
Zoetis Inc. has declared a dividend of $0.375 per share for the fourth quarter of 2023, payable on December 1. This announcement highlights Zoetis' commitment to returning value to shareholders. The company continues to focus on advancing animal health and has a robust portfolio that serves diverse clients globally, including veterinarians and livestock farmers. Despite the positive outlook, forward-looking statements made by the company carry inherent risks and uncertainties.
Read more →ZTSZoetis Announces Second Quarter 2023 Results Reports Revenue of $2.2 Billion, Growing 6%, and Net Income of $671 Million, or $1.45 per Diluted Share, Increasing 27% and 29%, Respectively, on a Reported Basis for Second Q
Zoetis Inc. announced its financial results for the second quarter of 2023, reporting a revenue increase of 6% year-over-year, reaching $2.2 billion. The company's net income rose to $671 million, marking a 27% increase, while operational growth in adjusted net income was reported at 12%. Despite maintaining a positive growth outlook, the company updated its full year revenue guidance to account for fluctuations in foreign exchange rates. Highlights included strong performance in the companion animal portfolio and innovations approved for pain management treatments.
Read more →ZTSInvestor Contacts Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price zoetis.com steve.frank zoetis.com Kristen Seely Nick Soonthornchai 1-973-443-2777 (o) 1-973-443-2792 (o) kristen
Zoetis Inc. has announced a dividend of $0.375 per share for the third quarter of 2023, which will be distributed to stockholders on September 1, 2023. The company, known for its leadership in animal health, has reported significant revenue and aims to advance care for animals globally. This dividend declaration reflects Zoetis's stable financial performance and ongoing commitment to its shareholders and the animal health sector.
Read more →ZTSZoetis Announces First Quarter 2023 Results Reports Revenue of $2.0 Billion, Growing 1%, and Net Income of $552 Million, or $1.19 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for First Quart
Zoetis Inc. reported its first-quarter results for 2023, showing a revenue of $2.0 billion, reflecting a 1% increase from the previous year. However, net income declined by 7% to $552 million, with adjusted net income down 3%. Despite these challenges, Zoetis maintains its full-year revenue guidance, projecting a growth of 6% to 8%. The company's international segment showed solid operational growth, particularly in livestock products, although the U.S. companion animal product sales faced declines due to short-term distributor actions.
Read more →ZTS▲ +5.4%on this news
Zoetis Reports Fourth Quarter and Full Year 2022 Results For Fourth Quarter 2022, Zoetis Reports Revenue of $2.0 Billion, Growing 4%, and Net Income of $461 Million, or $0.99 per Diluted Share, on a Reported Basis Delive
Zoetis Inc. has released its financial results for the fourth quarter and full year 2022, reporting a revenue of $2.0 billion for Q4 and $8.1 billion for the full year, both reflecting a 4% increase year-over-year. The company achieved operational growth of 9% in Q4 revenue and 8% for the full year. Adjusted net income saw significant growth, with a reported increase of 27% operationally for Q4 2022. Looking ahead, Zoetis provided guidance for 2023, anticipating revenue between $8.575 billion and $8.725 billion, which equates to operational growth of 6% to 8%.
Read more →ZTS▼ -11%on this news
Zoetis Announces Third Quarter 2022 Results Reports Revenue of $2.0 Billion, Growing 1%, and Net Income of $529 Million, or $1.13 per Diluted Share, Decreasing 4% and 3%, Respectively, on a Reported Basis for Third Quart
Zoetis Announces Third Quarter 2022 Results Reports Revenue of $2.0 Billion, Growing 1%, and Net Income of $529 Million, or $1.13 per Diluted Share, Decreasing 4% and 3%, Respectively, on a Reported Basis for Third Quarter 2022 Delivers 5% Operational Growth in Revenue and 2% O
Read more →ZTSDocument Media Contacts Investor Contacts Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price zoetis.com steve.frank zoetis.com Kristen Seely Nick Soonthornchai 1-973-443-2777 (o) 1-973-443-2792 (o
Media Contacts Investor Contacts Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price zoetis.com steve.frank zoetis.com Kristen Seely Nick Soonthornchai 1-973-443-2777 (o) 1-973-443-2792 (o) kristen.seely zoetis.com nick.soonthornchai zoetis.com Zoet
Read more →ZTSZoetis Announces Second Quarter 2022 Results Reports Revenue of $2.1 Billion, Growing 5%, and Net Income of $529 Million, or $1.12 per Diluted Share, Increasing 3% and 5%, Respectively, on a Reported Basis for Second Qua
Zoetis Announces Second Quarter 2022 Results Reports Revenue of $2.1 Billion, Growing 5%, and Net Income of $529 Million, or $1.12 per Diluted Share, Increasing 3% and 5%, Respectively, on a Reported Basis for Second Quarter 2022 Delivers 8% Operational Growth in Revenue and 9%
Read more →ZTSZoetis Announces First Quarter 2022 Results Reports Revenue of $2.0 Billion, Growing 6%, and Net Income of $595 Million, or $1.26 per Diluted Share, Increasing 6% and 8%, Respectively, on a Reported Basis for First Quart
Zoetis Announces First Quarter 2022 Results Reports Revenue of $2.0 Billion, Growing 6%, and Net Income of $595 Million, or $1.26 per Diluted Share, Increasing 6% and 8%, Respectively, on a Reported Basis for First Quarter 2022 Delivers 9% Operational Growth in Revenue and 8% O
Read more →ZTSZoetis Reports Fourth Quarter and Full Year 2021 Results For Fourth Quarter 2021, Zoetis Reports Revenue of $2.0 Billion, Growing 9%, and Net Income of $414 Million, or $0.87 per Diluted Share, on a Reported Basis Report
Zoetis Reports Fourth Quarter and Full Year 2021 Results For Fourth Quarter 2021, Zoetis Reports Revenue of $2.0 Billion, Growing 9%, and Net Income of $414 Million, or $0.87 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $474 Million, or Adjusted Diluted
Read more →ZTSZoetis Announces Third Quarter 2021 Results Reports Revenue of $2.0 Billion, Growing 11%, and Net Income of $552 Million, or $1.16 per Diluted Share, Increasing 15% and 16%, Respectively, on a Reported Basis for Third Qu
Zoetis Announces Third Quarter 2021 Results Reports Revenue of $2.0 Billion, Growing 11%, and Net Income of $552 Million, or $1.16 per Diluted Share, Increasing 15% and 16%, Respectively, on a Reported Basis for Third Quarter 2021 Reports Adjusted Net Income of $597 Million, or
Read more →ZTSInvestor Contacts: Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price@zoetis.com steve.frank@zoetis.com Kristen Seely Keith Gaub 1-973-443-2777 (o) 1-973-822-
Media Contacts: Investor Contacts: Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price@zoetis.com steve.frank@zoetis.com Kristen Seely Keith Gaub 1-973-443-2777 (o) 1-973-822-7154 (o) kristen.seely@zoetis.com keith.gaub@zoetis.com Zoetis Announces A
Read more →ZTSZoetis Announces Second Quarter 2021 Results Reports Revenue of $1.9 Billion, Growing 26%, and Net Income of $512 Million, or $1.07 per Diluted Share, Increasing 36% and 35%, Respectively, on a Reported Basis for Second
Zoetis Announces Second Quarter 2021 Results Reports Revenue of $1.9 Billion, Growing 26%, and Net Income of $512 Million, or $1.07 per Diluted Share, Increasing 36% and 35%, Respectively, on a Reported Basis for Second Quarter 2021 Reports Adjusted Net Income of $566 Million,
Read more →ZTS: Investor Contacts : Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price@zoetis.com steve.frank@zoetis.com Kristen Seely Keith Gaub 1-973-443-2777 (o) 1-973-82
Media Contacts : Investor Contacts : Bill Price Steve Frank 1-973-443-2742 (o) 1-973-822-7141 (o) william.price@zoetis.com steve.frank@zoetis.com Kristen Seely Keith Gaub 1-973-443-2777 (o) 1-973-822-7154 (o) kristen.seely@zoetis.com keith.gaub@zoetis.com Zoetis Announces
Read more →ZTSZoetis Announces First Quarter 2021 Results Reports Revenue of $1.9 Billion, Growing 22%, and Net Income of $559 Million, or $1.17 per Diluted Share, Increasing 32% and 33%, Respectively, on a Reported Basis for First Qu
Zoetis Announces First Quarter 2021 Results Reports Revenue of $1.9 Billion, Growing 22%, and Net Income of $559 Million, or $1.17 per Diluted Share, Increasing 32% and 33%, Respectively, on a Reported Basis for First Quarter 2021 Reports Adjusted Net Income of $603 Million, or
Read more →ZTSZoetis Reports Fourth Quarter and Full Year 2020 Results For Fourth Quarter 2020, Zoetis Reports Revenue of $1.8 Billion, Growing 8%, and Net Income of $359 Million, or $0.75 per Diluted Share, on a Reported Basis Report
Zoetis Reports Fourth Quarter and Full Year 2020 Results For Fourth Quarter 2020, Zoetis Reports Revenue of $1.8 Billion, Growing 8%, and Net Income of $359 Million, or $0.75 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $438 Million, or Adjusted Diluted
Read more →ZTSZoetis Announces Third Quarter 2020 Results Reports Revenue of $1.8 Billion, Growing 13%, and Net Income of $479 Million, or $1.00 per Diluted Share, Both Increasing 11% on a Reported Basis, for Third Quarter 2020 Report
Zoetis Announces Third Quarter 2020 Results Reports Revenue of $1.8 Billion, Growing 13%, and Net Income of $479 Million, or $1.00 per Diluted Share, Both Increasing 11% on a Reported Basis, for Third Quarter 2020 Reports Adjusted Net Income of $524 Million, or Adjusted Diluted
Read more →ZTSZoetis Announces Second Quarter 2020 Results Reports Flat Revenue of $1.5 Billion, and Net Income of $377 Million, or $0.79 per Diluted Share, Increasing 2% and 3%, Respectively, on a Reported Basis for Second Quarter 20
Zoetis Announces Second Quarter 2020 Results Reports Flat Revenue of $1.5 Billion, and Net Income of $377 Million, or $0.79 per Diluted Share, Increasing 2% and 3%, Respectively, on a Reported Basis for Second Quarter 2020 Reports Adjusted Net Income of $427 Million, or Adjuste
Read more →ZTSZoetis Announces First Quarter 2020 Results Reports Revenue of $1.5 Billion, Growing 5%, and Net Income of $423 Million, or $0.88 per Diluted Share, Increasing 36% and 35%, Respectively, on a Reported Basis for First Qua
Zoetis Announces First Quarter 2020 Results Reports Revenue of $1.5 Billion, Growing 5%, and Net Income of $423 Million, or $0.88 per Diluted Share, Increasing 36% and 35%, Respectively, on a Reported Basis for First Quarter 2020 Reports Adjusted Net Income of $455 Million, or
Read more →ZTSZoetis Reports Fourth Quarter and Full Year 2019 Results For Fourth Quarter 2019, Zoetis Reports Revenue of $1.7 Billion, Growing 7%, and Net Income of $384 Million, or $0.80 per Diluted Share, on a Reported Basis Report
Zoetis Reports Fourth Quarter and Full Year 2019 Results PARSIPPANY, N.J. - Feb. 13, 2020 - Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2019 and provided full year guidance for 2020. The company reported revenue of $1.7 bill
Read more →ZTSunderlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement.
FOR IMMEDIATE RELEASE: Media Contacts : Investor Contacts : Christina Lood Steve Frank 1-973-822-7249 (o) 1-973-822-7141 (o) christina.lood@zoetis.com steve.frank@zoetis.com Kristen Seely Marissa Patel 1-973-443-2777 (o) 1-973-443-2996 (o) kristen.seely@zoetis.com marissa
Read more →Competitive Position
How ZTS ranks across every disease it competes inCompetitive Position is a premium feature
See how ZTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial